Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.
J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.
Similar articles
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.
Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA.
Eur Urol. 2008 May;53(5):950-9. Epub 2007 Oct 12.
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.
Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT.
Eur Urol. 2007 Apr;51(4):940-7; discussion 947-8. Epub 2006 Oct 30.
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA.
J Urol. 2007 Aug;178(2):493-9; discussion 499. Epub 2007 Jun 11.
Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy.
Eggener SE, Yossepowitch O, Serio AM, Vickers AJ, Scardino PT, Eastham JA.
Urology. 2007 Jun;69(6):1128-33.
Role of radical prostatectomy in the treatment of high-risk prostate cancer.
Yossepowitch O, Eastham JA.
Curr Urol Rep. 2008 May;9(3):203-10. Review.
Radical prostatectomy for high-risk prostate cancer.
World J Urol. 2008 Jun;26(3):219-24. doi: 10.1007/s00345-008-0247-2. Epub 2008 Mar 12. Review.
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor.
Yossepowitch O, Sircar K, Scardino PT, Ohori M, Kattan MW, Wheeler TM, Reuter VE.
J Urol. 2002 Nov;168(5):2011-5.
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ.
J Urol. 2006 Oct;176(4 Pt 1):1399-403.
Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ.
Urology. 2008 Jun;71(6):1016-9. doi: 10.1016/j.urology.2007.12.008. Epub 2008 Mar 21.
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.
Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz PI, Montironi R, Montorsi F.
Eur Urol. 2009 Jan;55(1):87-99. doi: 10.1016/j.eururo.2008.09.051. Epub 2008 Oct 1. Review.
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT.
J Clin Oncol. 2009 Sep 10;27(26):4300-5. doi: 10.1200/JCO.2008.18.2501. Epub 2009 Jul 27.
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI.
BJU Int. 2011 Mar;107(5):765-770. doi: 10.1111/j.1464-410X.2010.09594.x. Epub 2010 Sep 28.
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.
Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P.
J Urol. 2008 Sep;180(3):873-8; discussion 878. doi: 10.1016/j.juro.2008.05.006. Epub 2008 Jul 17.
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P.
J Urol. 2008 Jun;179(6):2158-63. doi: 10.1016/j.juro.2008.01.100.
Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
J Urol. 2006 Aug;176(2):482-5.
Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome.
McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P.
Urology. 2002 Dec;60(6):1003-9.
Comparisons of nomograms and urologists' predictions in prostate cancer.
Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW.
Semin Urol Oncol. 2002 May;20(2):82-8. Review.
Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function.
Yossepowitch O, Eggener SE, Serio A, Huang WC, Snyder ME, Vickers AJ, Russo P.
J Urol. 2006 Oct;176(4 Pt 1):1339-43; discussion 1343.
ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.
Palou J, Wood D, Bochner BH, van der Poel H, Al-Ahmadie HA, Yossepowitch O, Soloway MS, Jenkins LC; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.
Eur Urol. 2013 Jan;63(1):81-7. doi: 10.1016/j.eururo.2012.08.011. Epub 2012 Aug 14. Review.
Filters: Manage Filters